Under a tenth of individuals eligible to benefit from weight-loss injections like Wegovy are able to get them, states the WHO as it issues its first guidance on the drugs.
Considering over a billion individuals worldwide now obese, it is calling for more widespread and fairer availability to this class of drugs.
According to forecasts, in excess of 2,000,000,000 are projected to be obese by 2030 without intervention.
"Our latest guidance acknowledges that obesity is a long-term condition that can be addressed with thorough and continuous support," stated WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are major barriers to broad availability to the injections that can assist patients in reducing substantial weight, explains the body.
Weight-Loss Drug Supply Crisis
Even under the present best projected outlook, the production of GLP-1 therapies would only suffice for approximately 100 million people – fewer than 10% of eligible patients, per the health organization.
The guideline encourages governments and firms to widen availability, via measures such as licensing agreements.
A patent on the active ingredient – the main ingredient of a leading brand – is set to lapse in a number of nations in 2026.
The Way Weight-Loss Jabs Work
The injections replicate a natural hormone to slow digestion, curb appetite and enhance feelings of fullness so individuals eat less.
People typically begin shedding pounds within a few weeks of beginning the regular doses.
Research points to patients may put most of the weight back on a year later of stopping the drug, because their normal hunger resume.
To be carrying excess weight increases your chance for contracting health problems, including diabetes, cardiovascular issues, brain attack, and specific cancers.
Obesity impacts individuals in all nations and was linked to 3.7 million fatalities worldwide in 2024, per the health agency.
